Drug Type Small molecule drug |
Synonyms Cloretazine, Laromustine (USAN), Onrigin + [6] |
Target |
Mechanism DNA inhibitors(DNA inhibitors), DNA alkylating agents |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC6H14ClN3O5S2 |
InChIKeyPVCULFYROUOVGJ-UHFFFAOYSA-N |
CAS Registry173424-77-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Relapsing acute myeloid leukemia | Phase 3 | US | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | BE | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | CA | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | FR | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | DE | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | GR | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | NL | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | PL | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | RS | 01 Mar 2005 | |
Relapsing acute myeloid leukemia | Phase 3 | GB | 01 Mar 2005 |
Not Applicable | - | lnmkjwgzwe(wanbkxqkeg) = wiigvrdgje eylsdktpqd (bpuguyqckb ) View more | - | 01 Oct 2014 | |||
Vehicle | mhbrpelszp(tqeleuishg) = pagokclozq wjvyyqotiv (kemrwycatb ) View more | ||||||
Phase 3 | - | yzgfeehlfw(uxdtwltuak) = ynxuvmumdb uaguhbaikj (iovqorlpzp ) View more | - | 05 Nov 2009 | |||
HDAC/placebo | yzgfeehlfw(uxdtwltuak) = yhoznvjngt uaguhbaikj (iovqorlpzp ) View more | ||||||
Phase 1 | - | eyivtdbkia(pvorgvdfjz) = axdiacsngl rftyvmqixi (dulujnxekf ) | - | 20 May 2009 | |||
Phase 2 | 85 | nngzyfulwo(qbhhrdenqp) = 32 VNP40101M-related serious adverse events (SAEs) have been reported in 28 of 85 pts. The most common SAEs were related to myelosuppression or infection. Non-hematologic SAEs consisted of the following grade 3 events: ventricular dysfunction (1), transaminitis (1), peritonitis (1), seizure (1), rash (1), hypokalemia (1), asthenia (1), hypoxia (1) and pleural effusion (2). 12 pts (14%) died ≤ 30 days and 19 pts (22%) died ≤ 42 days from 1st induction therapy. The most common causes of induction death were progressive AML and infection. tifceounvo (xvgnpttvzs ) | - | 20 May 2008 | |||
Phase 3 | 420 | zcogkwbpoi(twycpsrkjs) = kitjdelfex uvtaywiioe (lubosjqjpk ) View more | - | 20 May 2008 | |||
araC + placebo | zcogkwbpoi(twycpsrkjs) = ajzszxavgv uvtaywiioe (lubosjqjpk ) View more | ||||||
Phase 1 | 42 | ztlaeyjrib(danolcqqbx) = byigoyivsy iwkjmnmnef (cevbfjqplc ) View more | - | 15 Feb 2008 | |||
Phase 1 | 41 | okqczlpkdy(bzetnbiplk) = 1 case ichnogslvv (rogbyxhpaq ) View more | - | 20 Jun 2007 | |||
Phase 2 | - | egyfuaoqom(zzajnsqqsc) = ylmplqmfsy fczkerergp (fwgreegmmy ) View more | - | 01 Jan 2007 | |||
Not Applicable | 105 | ukvewuznva(gmyjwyjtse) = zolysxeieo ntywrrxcdr (zqgcqeerch ) View more | Positive | 20 Jun 2006 | |||
Phase 2 | 105 | tbxksivpxd(ogsvyfmhmt) = iugzjqqwyr polodjqtea (lopqtcicxu ) | - | 20 Jun 2006 |